Working… Menu

Evaluating a CytoSorb Score in Septic Shock (ECSISS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03977688
Recruitment Status : Completed
First Posted : June 6, 2019
Last Update Posted : February 19, 2020
Kantonsspital Münsterlingen
Universitätsklinikum Hamburg-Eppendorf
Kantonsspital Baden
Information provided by (Responsible Party):
Klaus Kogelmann, Klinikum Emden

Tracking Information
First Submitted Date June 3, 2019
First Posted Date June 6, 2019
Last Update Posted Date February 19, 2020
Actual Study Start Date March 1, 2019
Actual Primary Completion Date May 30, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: June 5, 2019)
Hospital mortality [ Time Frame: through study completion, an average of 49 days ]
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures
 (submitted: June 5, 2019)
Icu mortality [ Time Frame: through study completion, an average of 49 days ]
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title Evaluating a CytoSorb Score in Septic Shock
Official Title Evaluating a CytoSorb Score in Septic Shock - a Retrospective Multicenter Data Analysis
Brief Summary

Systemic hyperinflammatory states, e.g. triggered by infection/sepsis, represent a major challenge for modern medicine. After an initially localized onset, inflammation can extend to an excessive, uncontrolled inflammatory reaction affecting the entire body and can trigger circulatory failure with subsequent irreversible multiple organ failure. Despite all the medical advances made in recent years, sepsis continues to be a substantial problem, as almost all therapeutic approaches have failed to prove their efficacy to date. Mortality in this clinical entity thus remains extremely high. In Germany alone, more than 100,000 people suffer from sepsis or septic shock every year, nearly half of whom die despite optimal therapy. Thus, sepsis is the third most common cause of death, has major importance both from a medical but also from an economical viewpoint, and approaches that could contribute to its successful treatment need to be further developed and explored.

If a patient experiences the spread of bacteria or their constituents in the blood stream due to an uncontrolled source of infection, the result is a deliberately triggered physiological defense reaction of the body. In many patients, however, there is a pathological dysregulation of these mechanisms, in a way that the defense reaction goes far beyond the physiological level required, resulting in an excessive immune response of the body, which is mainly facilitated by inflammatory mediators such as cytokines and chemokines. The immune response spreads throughout the body and also dissipates into organs unaffected by the original infection. In cases of such unwanted overshooting immune responses, an attempt to regain control of the described deleterious systemic events seems reasonable by removing the excess amount of cytokines from the blood, thus preventing or treating organ failure.

In this context, current therapeutic approaches increasingly focus on the elimination of inflammatory mediators.

In recent years, hemoadsorption, using a new adsorber (CytoSorb), has been used to treat sepsis and other conditions of hyperinflammation. The advantage of this therapeutic principle is that a wide range of inflammatory mediators are removed. In conjunction with the enormous elimination capacity, the effective and rapid reduction of mediators can be achieved.

To date, there have been more than 61,000 treatments using this procedure worldwide without device-related side effects being reported. The investigators have been treating patients with this procedure for over 5 years with consistently very favorable results. Therefore, the investigators would like to expand and deepen their observations with the proposed project.

Detailed Description

The primary effects of CytoSorb therapy, are, among many others, an improvement in hemodynamics, metobolism, and capillary integrity, with effects of adsorption seeming to reach far beyond mere cytokine adsorption.

Clinically, several publications have shown that certain patient populations benefit most from adjuvant CytoSorb treatment.

In a case series from the investigators department, they examined the effects of CytoSorb as an adjunctive therapy on hemodynamics and on clinically relevant outcome parameters in 26 patients with septic shock and the indication for renal replacement therapy. Treatment was associated with hemodynamic stabilization and reduction in blood lactate levels. The actual mortality was lower than predicted by APACHE II score. This effect was more pronounced in patients in whom therapy was initiated within 24 hours of sepsis diagnosis. Medical patients seemed to benefit more than post-surgical patients in terms of survival.

Based on these results, the investigators performed another study in seven patients with septic shock and ECMO (extracorporeal membrane oxygenation)-dependent acute respiratory distress syndrome (ARDS) treated with a combination therapy of CytoSorb, continuous renal replacement therapy (CRRT) and veno-venous ECMO. The combined treatment was associated with a significant stabilization in hemodynamics and a marked reduction in hyperlactatemia. In addition, patients also showed a significant improvement in lung function and invasiveness of ventilation, and the disease severity and organ dysfunction decreased significantly over the course of the combined treatment, while the observed mortality was only half that predicted by the APACHE II score. The investigators conclude that CytoSorb may be a potentially promising treatment option for patients with refractory ARDS under ECMO therapy in the context of septic shock.

Friesecke et al. prospectively investigated CytoSorb cytokine adsorption in combination with standard of care in 20 patients with refractory septic shock (defined as increasing vasopressor dosages to maintain a MAP of 65mmHg or increasing lactate levels despite protocol-based shock therapy over 6 hours). CytoSorb therapy was started on average after 7.8±3.7 hours of shock therapy. After initiating CytoSorb, norepinephrine dosages could be significantly reduced both after 6 (p=0.03) and 12 (p=0.001) hours. Lactate clearance also improved significantly. Reversal of septic shock was achieved in 13 (65%) patients, with a 28-day survival rate of 45% (with a SOFA predicted mortality of >80%). Treatment with CytoSorb resulted in shock reversal in 2/3 of these difficult-to-treat patients. Data from the CytoSorb registry also support these observations.

In summary, these data show that certain subgroups of patients (in particular those with pneumonia as well as the most critically ill patients with an APACHE score >35) particularly benefit from CytoSorb treatment and that an early onset of therapy (at best <24 hours after diagnosis of septic shock) appears to be beneficial and associated with an increased survival rate.

Given the available information, the investigators analyzed their existing data for dynamic scoring of the first 6 hours in septic shock, based on the study by Ferreira et al. This study showed, that a trend assessment of the SOFA score during the first few days after admission to the intensive care unit allowed for a very good prognosis of the patient's eventual outcome.

The Investigators retrospectively screened data using threshold values for lactate, catecholamine demand, volume requirements, and the need for additional adjuvant therapy with a second catecholamine, and or the application of hydrocortisone.

In this first data analysis, there was an advantage in terms of survival in those patients with pneumonia, in those where Cytosorb therapy was started at least within the first 24 hours of refractory shock, and in patients with slightly higher scores. The investigators subsequently collected this retrospective score in all patients treated at their department who were diagnosed with septic shock according to sepsis-3 criteria in the years 2014-2018. Once again, the benefit - this time also compared to non-Cytosorb-treated patients - could be confirmed.

In order to validate these internal data against neutral other patients, the investigators plan the retrospective data analysis described herein performed as a multi-center study with 3 additional departments which also use CytoSorb therapy. The project involves colleagues from Switzerland (Dr. Hübner, Münsterlingen), Germany (Dr. Jarczak, UK Eppendorf Hamburg) and from Austria (Dr. Schwameis, Baden). Overall, data from approximately 500 patients will be retrospectively collected and analyzed (of which approximately 1/3 patients have been treated with CytoSorb).

The aim is to create a new assessment system based on established, clinically well-available parameters such as lactate, volume and catecholamine therapy to identify patients with early refractory septic shock (Sepsis-3), who would benefit most from adjuvant therapy with Cytosorb hemoadsorption.

For this purpose, physiological patient-related treatment data from patients with septic shock who received CytoSorb treatment will be retrospectively compared to a control group that did not receive this treatment.

Patients who meet the above mentioned inclusion criteria, i.e. who are in a state of septic shock according to the Sepsis-3 definition (sepsis + catecholamine therapy and volume therapy + lactate >2 mmol/l) will be included. Data of included patients will be entered into a data matrix (see chapter 'Assessed parameters'). Each parameter is documented at the time of diagnosis of septic shock as well as 6 hours later to analyze the dynamic process in the early phase of septic shock. The threshold values are based on Sepsis-3 criteria of septic shock (lactate level >2 mmol/l), the administration of norepinephrine according to the SOFA score (norepinephrine > 0.2 μg/kg/min) and volume requirement according to the Surviving Sepsis Guidelines (initial bolus 30 ml/kg body weight).

Each pathological value is rated with 2 points. Decreasing values or no change during the 6 hours observation period receive no points, increasing values receive 1 point, increasing values >50% of the initial value receive 2 points (see data matrix). If <2 volume boluses are necessary, this is rated with 1 point, when ≥2 boluses are necessary within 6 hours, this is scored with 2 points.

In this matrix, septic shock is typically represented by a score of 5 points. Six or more points indicate a situation that is no longer responsive to standard therapy. All data are stored in the respective HIS of the hospitals involved and can be accessed. Centralized data processing will take place at the Department of Anaesthesiology and Intensive Care Medicine at Emden Hospital. The investigators will provide their data anonymously in a tabular format.

Each parameter at the time of septic shock diagnosis (T0h) and 6 hours (T6h) later is documented to analyze the dynamic process in early septic shock.

In addition, values for laboratory diagnostic parameters are also collected 3 days after the diagnosis of septic shock (T72h).

The personal data and findings collected as part of this research project are subject to confidentiality and data protection regulations. They are recorded on paper and stored pseudonymized (encrypted) on data carriers in the participating institutions for a period of 10 years. Name and other identifiers are replaced by a multi-digit code to exclude or substantially complicate the identification of study participants. Only the respective study physician in his or her own center has access to the code which allows a personal assignment of the data of the study participant. As soon as the research purpose allows, the code will be deleted and the data collected will be anonymized. Only the respective study physician can access the data of the patients in their own center. The data are transmitted in a tabular format without any possibility of identification (neither patient-related nor time-related) to the principal study center (Emden Hospital) and provided there with a consecutive number. Access to the data of the individual participating study centers is not possible.

Study Type Observational
Study Design Observational Model: Other
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population each patient eligible with icu treated refractory septic shock in the last 4 years
Condition Severe Sepsis With Septic Shock
Intervention Device: Cytokin Adsorption
Haemadsorption with Cytokin Adsorber (Cytosorb)
Study Groups/Cohorts
  • none Cyto
    septic shock, refractory, without Cytokin-adsorption therapy
  • cyto
    septic shock, refractory, treated with Cytokin-adsorption therapy
    Intervention: Device: Cytokin Adsorption
Publications *

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: June 5, 2019)
Original Estimated Enrollment Same as current
Actual Study Completion Date December 30, 2019
Actual Primary Completion Date May 30, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • septic shock according Sepsis 3 criteria

Exclusion Criteria:

  • no data available, no icu treatment
Sexes Eligible for Study: All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers Not Provided
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Germany
Removed Location Countries  
Administrative Information
NCT Number NCT03977688
Other Study ID Numbers 20194
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: Undecided
Responsible Party Klaus Kogelmann, Klinikum Emden
Study Sponsor Klinikum Emden
  • Kantonsspital Münsterlingen
  • Universitätsklinikum Hamburg-Eppendorf
  • Kantonsspital Baden
Principal Investigator: Klaus Kogelmann, MD head of department
PRS Account Klinikum Emden
Verification Date February 2020